Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
April 13, 2009
- Hansha's Sales Forces May Help Generics Makers Provide Information
April 13, 2009
- JCS (Japanese Circulation Society) 2009
April 13, 2009
- Mylan Seiyaku Kicks Off Cancer-Specialized Team
April 13, 2009
- Lucentis to Become the Mainstay for AMD in Japan as Well
April 13, 2009
- Society of Applied Therapeutics to Be Inaugurated
April 13, 2009
- Optimal Antiviral Therapy Important to Prevent Liver Cancer: Dr Izumi
April 13, 2009
- Daiichi Sankyo to Apply for DU-176b as Japan's First Oral Anti-Xa Agent
April 13, 2009
- Synergistic Effects Can Be Expected with Adoair
April 13, 2009
- Daiichi Sankyo Reshuffles R&D Structures to Quickly Develop Biologics
April 13, 2009
- UFT as Effective as CMF for Postoperative Breast Cancer
April 13, 2009
- InCROM Clinical Research Unit Certified by MHRA
April 13, 2009
- Supportive Care Perspectives 2008 (SCP2008) from Synix
April 13, 2009
- R&D NEWS IN BRIEF
April 13, 2009
- Bayer to Pursue Growth Rate Twice as High as Industry Average
April 13, 2009
- FDA's Advisory Committee Recommends Approval for ONGLYZA
April 13, 2009
- Takeda Further Globalizes Its Business Structure
April 13, 2009
- Celgene to File an NDA for Lenalidomide in 2010
April 13, 2009
- Chugai Will Remain Independent Despite Acquisition of Genentech by Roche
April 13, 2009
- Daiichi Sankyo Sues 13 Companies for Levofloxacin Patent Violation
April 6, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…